15 results about "Mammalian Embryos" patented technology

The invention provides an application of a CTH inhibitor and / or an xCT inhibitor in preparation of a medicine for inhibiting mammal embryo implantation, and relates to the technical field of medicines. The application effect of a cystathionine-gamma-lyase (CTH) inhibitor and / or a solute carrier family 7 member 11 (xCT) inhibitor in inhibition of mammalian embryo implantation is verified through research. The research result shows that the xCT inhibitor and / or the CTH inhibitor can obviously inhibit proliferation of corpus luteinized granular cells and secretion of progesterone of a model mouse; meanwhile, by injecting the xCT inhibitor and / or the CTH inhibitor into the mouse model in vivo, ovary ovulation and the maturation rate of the ovulated oocyte nucleus can be remarkably inhibited, functional corpus luteum formation and embryo implantation can be remarkably reduced, and then a new thought and method are provided for development of contraceptive drugs.

This invention provides the application of CTH inhibitors and / or xCT inhibitors in the preparation of drugs for inhibiting mammalian embryo implantation, relating to the field of pharmaceutical technology. This invention verifies the efficacy of cystathionine-γ-lyase (CTH) inhibitors and / or solute carrier family 7 member 11 (xCT) inhibitors in inhibiting mammalian embryo implantation. The results show that xCT inhibitors and / or CTH inhibitors can significantly inhibit the proliferation of luteinized granulosa cells and progesterone secretion in mouse models. Furthermore, in vivo injection of xCT inhibitors and / or CTH inhibitors into mouse models not only significantly inhibits ovulation and the maturation rate of released oocytes, but also significantly reduces the formation of functional corpus luteum and embryo implantation. Therefore, this application provides new ideas and methods for the development of contraceptive drugs.

The present disclosure provides a method for promoting in vitro development of mammalian embryos, comprising the step of adding alpha-ketoglutarate in the embryo development fluid at 90-180h after in vitro fertilization. Compared with the method of adding throughout the whole embryo development, the present disclosure finds that the promotion of embryo development efficiency is more significant when alpha-ketoglutarate is added after 90 hours after fertilization (90 hours to 180 hours after fertilization).

The invention provides application of an RTL6 gene in improvement of an in-vitro embryo development rate, and relates to the technical field of mammal embryo engineering. According to the present invention, the RTL6 gene is constructed into the PcDNA3.1 (+)-RTL6 recombinant vector, and the pcDNA3.1 (+)-RTL6 recombinant vector is injected into the in vitro mature oocyte cytoplasm 4-5 h after the pig parthenogenetic activation, such that the embryonic development retardation phenomenon is effectively relieved, and the embryonic development is promoted;

Provided is a method for acquiring mammalian embryos having a high fecundation rate.　The embryos are acquired via step a) and step b), as follows.　a) A step in which a trifunctional purine biosynthetic protein adenosine-3 homolog protein (GART) and / or a gene encoding GART is introduced into a fertilized mammalian ovum. b) A step in which the fertilized ovum is cultured.

Provided is a method for acquiring mammalian embryos having a high fecundation rate by culturing fertilized mammalian ova under suitable conditions.　The fertilized mammalian ova are cultured using a culture medium containing a glycine metabolism-related substance to acquire the embryos.

Provided herein include methods and compositions for single-cell proteomics analysis of mammalian embryos and uses thereof to screen perturbations and to detect perturbation-induced change in the protein composition of the mammalian embryos.

The invention includes a method of identifying high genomic value, non-human mammalian embryos that would otherwise be disposed of or frozen based on their morphology. The method generally involves establishing a stem cell culture from the non-human mammalian embryo, which entails generating a population of embryos in vitro or in vivo, assessing the morphology of each of the embryos in the population, selecting a subpopulation of embryos for embryo transfer based on the morphological assessment, thereby establishing a group of selected embryos and a group of unselected embryos in the population, and establishing a stem cell culture from an embryo in the group of unselected embryos.

Provided herein include methods and compositions for single-cell proteomics analysis of mammalian embryos and uses thereof to screen perturbations and to detect perturbation-induced change in the protein composition of the mammalian embryos.

The invention relates to a method for preparing neural stem cells with high multiplication capacity, and belongs to the technical field of biology. The method comprises the following steps: separating primary neural stem cells from mammal embryo brain tissues, taking DMEM / F12 as a basic culture medium, adding B27, N2, glutamine and double antibodies, and then adding epidermal growth factors, basic fibroblast growth factors, insulin-like growth factor-1, Y-27632 and heparin to form an optimized proliferation culture medium. The method comprises the following steps: inoculating cells into a culture dish coated with polylysine and laminin, culturing under proper conditions, and digesting and subculturing after neurospheres reach a certain diameter; the method can improve the proliferation efficiency of neural stem cells and maintain stemness and differentiation potential, adopts a serum-free system, is simple and convenient to operate, and is suitable for large-scale amplification and research application.

Method for selecting mammalian cells having a genetically-desirable trait, the method comprising culturing an embryo in vitro, dividing the cells from the embryo into aliquots, subjecting the cells from at least one of the aliquots to a genetic analysis, and, based on the results of such analysis, selecting an aliquot of cells. Method for selecting mammalian cells having a genetically-desirable trait, the method comprising culturing an embryo in vitro, transferring the cultured embryo into a recipient female, collecting the embryo, dividing the cells from the embryo into aliquots, subjecting the cells from at least one of the aliquots to a genetic analysis, and, based on the results of such analysis, selecting an aliquot of cells. Method for selecting a mammalian embryo having a genetically-desirable trait, the method comprising removing one or more cells from each of a plurality of embryos, culturing the cells, subjecting the cultured cells to a genetic analysis, and, based on the results of such analysis, selecting an embryo.

This invention discloses a method for inducing mouse embryonic stem cells to transition to a pluripotent state using H2BC21 and its application, belonging to the fields of molecular biology and stem cell engineering technology. By constructing an interference vector targeting the H2BC21 gene, packaging it with lentivirus, and infecting mouse embryonic stem cells, the expression of the H2BC21 gene is knocked down, and embryonic stem cell lines with stable low expression of H2BC21 are obtained through screening. This invention is the first to discover that H2BC21 is a core negative regulator of mammalian embryonic stem cell pluripotency. After knocking down H2BC21, the expression of pluripotency core genes Nanog, Oct4, and Sox2 is downregulated, while the expression of pluripotency core genes Zscan4b, Usp17la, and Tmem92 is upregulated. The cells exhibit molecular characteristics similar to 2-cell phase cells, successfully achieving the transition from pluripotency to a pluripotent state.

The invention includes a method of identifying high genomic value, non-human mammalian embryos that would otherwise be disposed of or frozen based on their morphology. The method generally involves establishing a stem cell culture from the non-human mammalian embryo, which entails generating a population of embryos in vitro or in vivo, assessing the morphology of each of the embryos in the population, selecting a subpopulation of embryos for embryo transfer based on the morphological assessment, thereby establishing a group of selected embryos and a group of unselected embryos in the population, and establishing a stem cell culture from an embryo in the group of unselected embryos.

To provide a culture medium composition capable of being used for culturing mammalian embryonic stem cells, the composition being free from serum and pituitary extract and also free from animal-derived proteins including albumin derived therefrom, and also to provide a culturing method using the culture medium composition.SOLUTION: A culture medium composition for three-dimensional culture of mammalian pluripotent stem cells, the composition containing (A1) activin, (A2) a TGFβ subfamily protein, (A3) a GSK3 inhibitor, (A4) a Wnt inhibitor, and (A5) polyvinyl alcohol (PVA), and containing none of (B) serum and pituitary extract and albumin derived therefrom and other animal-derived proteins. A culturing method including a step of culturing mammalian pluripotent stem cells in the culture medium composition under feeder-cell-free three-dimensional culture conditions.SELECTED DRAWING: None